Menopause accelerates biological aging by Levine, ME et al.
1 
 
Classification: BIOLOGICAL SCIENCES (Medical Sciences) 
 
Menopause Accelerates Biological Aging 
Morgan E. Levinea,b, Ake T. Lua, Brian H. Chenc, Dena G. Hernandezd, Andrew B. Singletond, 
Luigi Ferruccic, Stefania Bandinellie, Elias Salfatif, JoAnn E. Mansong, Austin Quacha, Cynthia 
D.J. Kustersh, Diana Kuhi, Andrew Wongi, Andrew E. Teschendorffj,k,l, Martin Widschwendterj, 
Beate R. Ritzh, Devin Absherm, Themistocles Assimesf, Steve Horvatha,n 
 
Affiliations 
aDepartment of Human Genetics, University of California Los Angeles, Los Angeles, CA 90095, USA. 
bCenter for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, 90095; 
USA. 
cLongitudinal Study Section, Translational Gerontology Branch, Intramural Research Program, National 
Institute on Aging, National Institutes of Health, Bethesda, MD, 20892; USA. 
dLaboratory of Neurogenetics, Intramural Research Program, National Institute on Aging, National 
Institutes of Health, Bethesda, MD, 20892; USA. 
eGeriatric Unit, Azienda Sanitaria di Firenze, 50100; Florence, Italy. 
fDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, 94305; USA 
gDepartment of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115; 
USA . 
hEpidemiology, School of Public Health, University of California Los Angeles, Los Angeles, CA 90095; 
USA 
iMedical Research Council Unit for Lifelong Health and Ageing at University College London, London, 
WC2B 4AN; United Kingdom 
jDepartment of Women’s Cancer & UCL Cancer Institute, University College London, London WC1 6BT; 
United Kingdom,  
kStatistical Genomics Group at the University College London Cancer Institute, London, WC1E 6DD; 
United Kingdom 
lCAS Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, 
Chinese Academy of Sciences, Shanghai Institute for Biol, Shanghai 200031; China. 
mHudsonAlpha Institute for Biotechnology, Huntsville, AL, 35806; USA 
nDepartment of Biostatistics, University of California Los Angeles, Los Angeles, CA, 90095; USA 
 
Corresponding Author: 
Steve Horvath (shorvath@mednet.ucla.edu) 
(310) 825-9299 
4357A Gonda Research Building 
Department of Human Genetics 
UCLA David Geffen School of Medicine 
Los Angeles, CA 90095-7088 
 
Keywords: Menopause, Aging, Epigenetics 
2 
 
Abstract 
While epigenetic processes have been linked to aging and disease in other systems, it is not yet 
known whether they relate to reproductive aging. Recently, we developed a highly accurate 
epigenetic biomarker of age (known as epigenetic clock) which is based on DNA methylation 
levels. Here we carry out an epigenetic clock analysis of blood, saliva, and buccal epithelium using 
data from four large studies: Women's Health Initiative (n=1,864), InCHIANTI (n=200), PEG 
(n=256), and the United Kingdom Medical Research Council National Survey of Health and 
Development (NSHD) (n=790). We find that increased epigenetic age acceleration in blood is 
significantly associated with earlier menopause (P=0.00091), bilateral oophorectomy (P=0.0034), 
and a longer time since menopause (P=0.017). Conversely, buccal epithelium and saliva do not 
relate to age at menopause, however lower epigenetic age is exhibited in women who undergo 
menopausal hormone therapy (P=0.00078). Using genetic data we find evidence of co-heritability 
between age at menopause and epigenetic age acceleration in blood. Using Mendelian 
randomization analysis we find that two SNPs that are highly associated with age at menopause 
exhibit a significant association with epigenetic age acceleration. Overall, our Mendelian 
randomization approach and other lines of evidence suggest that menopause accelerates epigenetic 
aging of blood, but mechanistic studies will be needed to further dissect cause-and-effect 
relationships. 
Significance Statement 
Within an evolutionary framework, aging and reproduction are intrinsically linked. While both 
laboratory and epidemiological studies have observed associations between the timing of 
reproductive senescence and longevity, it is not yet known whether differences in the age of 
menopause are reflected in biomarkers of aging. Using our recently developed biomarker of aging, 
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the “epigenetic clock”, we examined whether age at menopause is associated with epigenetic age 
of blood, saliva, and buccal epithelium. This is the first definitive study to show an association 
between age of menopause and biological aging (measured using the epigenetic clock). Our results 
also indicate menopause may accelerate the epigenetic aging process in blood and that age at 
menopause and epigenetic age acceleration share a common genetic signature. 
 
INTRODUCTION 
Reproductive senescence, concluding in menopause, is a feature of all female mammals(1), 
yet humans are unique in that they experience exceptionally long post-reproductive lifespans. 
Within human populations, the timing of menopause onset has been linked to susceptibility for 
age-related morbidity and mortality outcomes(1). For instance, observational studies have 
uncovered associations between a woman’s age at menopause and her subsequent risk of mortality. 
Results based on 12,134 Dutch women showed that for every one year increase in the age of 
menopause, age-adjusted mortality rate was decreased by 2%(2).  
While social/behavioral and developmental factors, such as smoking, lifetime 
socioeconomic circumstances , infant growth, breastfeeding, and childhood cognitive ability have 
been shown to influence reproductive aging, age at menopause is also considered to be highly 
heritable, with estimates from twin and sibling studies ranging from about 0.40-0.70(3-10). A 
recent large-scale genome-wide association study identified 44 genomic loci with common 
variants that significantly related to age at menopause(11), while a case-control study comparing 
centenarian women to those with average lifespans, found that individuals from families with a 
history of longevity also tend to exhibit delayed reproductive aging (12).  
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While these and other studies suggest that there might be a relationship between age at 
menopause and the biological aging rate, it has been difficult to test this hypothesis due to the 
dearth of molecular biomarkers of aging. Several recent articles describe epigenetic biomarkers of 
aging based on methylation levels(13-16), drawing upon the fact that chronological age has a 
profound effect on DNA methylation (DNAm) levels (17-26). While previous articles describe 
epigenetic age measures that only apply to a single tissue (saliva (13 ) or blood (14)), our recently 
developed "epigenetic clock" method (based on 353 CpGs) applies to every human tissue and cell 
type that contain DNA, with the exception of sperm(15). Age acceleration effects can be estimated 
by contrasting DNAm age with an individual’s chronological age. For instance, a woman whose 
blood has a higher DNAm age than expected based upon her chronological age, can be said to 
exhibit positive age acceleration—or can be thought of as aging faster than expected. Age 
acceleration has also been shown to have a strong genetic basis—with heritability estimates of 
40% for older subjects(15, 27). While the epigenetic clock has been shown to relate to a number 
of aging-related outcomes (27-30), it is not yet known whether it relates to reproductive aging. 
Using data from four large observational studies—Women's Health Initiative (WHI), 
InCHIANTI, PEG, and NSHD—we examine the association between epigenetic age and: age at 
menopause, bilateral oophorectomy, and the use of menopausal hormone therapies (MHT). Given 
the strong heritability of both age at menopause and epigenetic age, we also estimate the genetic 
correlation between age at menopause and epigenetic aging, and carry out a Mendelian 
randomization analysis, to examine causality, using the top two SNPs shown previously to be 
strongly associated with age at menopause(31).  
RESULTS  
Age acceleration of blood versus age at menopause 
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In our primary analysis, we consider only women whose menopause occurred after age 30. 
As shown in Table 1, based on result from Pearson correlations in each of our three blood datasets 
(WHI, InCHIANTI, and PEG), meta-analysis showed that age at menopause was significantly 
associated with epigenetic age acceleration (p=0.00091). Similar meta-analytic p-values were 
obtained in our secondary analysis, which excluded women with surgical menopause (p=0.0083), 
and in our tertiary analysis, which used all women regardless of age or type (natural/surgical) of 
menopause (p=0.0061). Pearson correlation results from individual studies and stratifying by 
race/ethnicity can be found in Figure S1. 
Multivariate linear models linking age acceleration with age at menopause 
 Using blood methylation data from WHI, InCHIANTI, and PEG we conducted multivariate 
regression for women who experienced menopause after age 30, and combined results using meta-
analysis to determine whether covariates accounted for the association between epigenetic age 
acceleration and age at menopause (Table 2). Models were adjusted for age, race/ethnicity (in 
WHI and PEG), smoking status, age at menarche, and MHT use. Additionally, models run using 
PEG data, were also adjusted for Parkinson’s disease (PD). In order to retain the moderate number 
of women with missing data on MHT use in PEG, those who were missing were coded as “never”, 
and a dummy variable for missing was added to the model. After adjusting for possible 
confounders we find that higher epigenetic age acceleration is associated with a younger age at 
menopause (Meta-p=8.32×10-4).  
Time since Menopause 
 To examine whether menopause may be contributing to accelerated aging, we tested the 
association between epigenetic aging and time since menopause, using multivariate models that 
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adjust for race/ethnicity (WHI and PEG), and smoking (Table S2). Results showed that the 
variable "time since menopause" was associated with AgeAccel (=0.038, P=0.007) in the WHI 
and in our meta-analysis (AgeAccel P=0.017). 
Surgical menopause is associated with epigenetic age acceleration 
The menopause of a substantial number of women was due to bilateral oophorectomy (i.e. 
n=127 women in WHI-white, 112 in WHI-black, 50 women in WHI-Hispanic, and 48 women in 
PEG). We evaluated the effect of surgical menopause on epigenetic age acceleration among 
women whose bilateral oophorectomy took place before age 50 (Figure 1). The association was 
highly consistent across the blood data sets (Figure 1) which led to a significant meta-analysis P-
value for all 3 measures of age acceleration: AgeAccel (Stouffer's Z=3.2. p=0.0014).  
Genetic correlation and Mendelian randomization between epigenetic age acceleration and age 
at menopause 
Using the WHI data (n=1,940), we conducted a bivariate REML analysis to examine the 
overlap in genetic variants that accounted for the heritability of both age at menopause and 
epigenetic age acceleration. As shown in Table 3, the 10,769,392 autosomal SNPs or INDEL 
markers included in the analysis accounted for about 38% of the variance in age at menopause and 
65% of the variance in AgeAccel. The genetic correlation (or pleiotropy) between AgeAccel and 
age of menopause was marginally significant with rG=-0.256 (one-sided P=0.054).  
Although we clearly demonstrate that age at menopause relates to epigenetic age 
acceleration, our cross sectional data make it difficult to dissect causal relationships. Mendelian 
randomization (reviewed in (32))—the random assortment of genes from parents to offspring that 
occurs during gamete formation and conception—provides one method for assessing the causal 
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nature of associations. Here we test the hypothesis that menopause leads to an acceleration of 
epigenetic aging by leveraging the two most highly significant SNPs from a genome-wide 
association study for age at menopause (rs11668344 Replication P-value= 2.65×10−18, rs16991615 
Replication P-value= 7.90×10−21). If menopause accelerates epigenetic aging then one would 
expect these two SNPs to also relate to epigenetic age acceleration, which is what was found 
(Table 4) for rs11668344 (P=0.031). Additionally, the directionality of the associations is 
consistent with the causal model (SNPage at menopauseage acceleration), i.e. the minor allele 
is associated with earlier age at menopause and higher epigenetic age acceleration. On the other 
hand, rs16991615 was not associated with epigenetic age acceleration (P=0.763).  
Analysis of buccal epithelium and saliva 
We are not aware of any biological reason that suggests that blood tissue stands out when 
it comes to studying menopausal effects. Several previous data sets demonstrate that the epigenetic 
clock method also applies to buccal epithelium (35). As a result, we also examined epigenetic age 
measured in 790 buccal epithelium samples from National Survey of Health and Development 
(NSHD) from the United Kingdom Medical Research Council.  
Unlike results in blood, MHT is associated with a significantly lower epigenetic age 
acceleration of buccal epithelium (p=0.00078, Figure 2A); whereas age at natural or surgical 
menopause does not correlate with epigenetic age acceleration across the n=419 postmenopausal 
buccal samples (Figure 2B and 2D, respectively); and no significant association was found 
between age acceleration and menopausal status at age 53—n=419 post- versus 371 pre-
menopausal samples (Figure 2C).  
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 We also analyzed saliva samples from 113 women from the PEG study of whom 16 had 
undergone surgical menopause. Similar to buccal epithelium, age at menopause and time since 
menopause were not associated with epigenetic age acceleration in saliva which might reflect the 
low sample size. However, surgical menopause was associated with increased AgeAccel of saliva 
(P=0.0079, Figure 3). 
DISCUSSION 
To the best of our knowledge, this is the first study that shows a) that the epigenetic age of 
blood has a negative correlation with age at menopause, b) that surgical menopause is associated 
with an increased epigenetic age of blood and saliva, c) that menopausal hormone therapy is 
inversely associated with epigenetic age acceleration of buccal epithelium, and d) that a SNP which 
relate to age at menopause also relates to epigenetic age acceleration. While our study 
demonstrates that postmenopausal women with a late onset of menopause are epigenetically 
younger than women with an early onset of menopause, it is challenging to dissect cause and effect 
relationships. In the following, we discuss several causal scenarios that could explain the reported 
findings (Fig. S2). 
The first causal model (age at menopause  Biological Age  Epigenetic age 
acceleration) assumes that both "age at menopause" and "epigenetic age acceleration" are indicator 
variables of a latent variable, which can be thought of as true biological age. There is evidence that 
risk factors for heart disease, which arguably accelerate biological age, are likely to contribute to 
an earlier age of menopause, rather than the commonly held notion that early menopause is a risk 
factor for heart disease(33). Consistent with evolutionary theories of aging, genetic predisposition 
to later menopause may coincide with an innate protection against early mortality(34). In this 
study, we observe a suggestive genetic correlation between age at menopause and epigenetic age 
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acceleration, which may suggest that increased age at menopause is genetically linked to decreased 
epigenetic age acceleration. This advocates for a common genetic etiology and is consistent with 
both variables being indirect measures of biological age—genetic variants which influence 
biological aging may therefore lead to both slower reproductive aging and lower epigenetic age.  
Another causal model assumes that menopause leads to an increase of epigenetic age. This 
model is supported by the following lines of evidence. First, we find that longer time since 
menopause (irrespective of age at menopause) is associated with increased epigenetic age 
acceleration. Second, bilateral oophorectomy is associated with increased epigenetic age 
acceleration in both blood and saliva. This finding is congruent with a growing body of evidence 
suggesting that the premature loss of ovarian function caused by bilateral oophorectomy performed 
before natural menopause contributes to increased susceptibility to premature death, 
cardiovascular disease, dementia, parkinsonism, osteoporosis and bone fractures(35). This is also 
consistent with findings showing that transplantation of young ovaries in old mice significantly 
increases lifespan(36). Third, our study demonstrated that MHT, which arguably counters some of 
the effects of menopause, is associated with a decreased epigenetic age acceleration of buccal 
epithelium (but not of blood). Fourth, our Mendelian randomization analysis provided evidence of 
a causal pathway in which menopause accelerates epigenetic aging in blood—one of the most 
significant SNPs (rs11668344) for age of menopause also relates to epigenetic age acceleration in 
blood. Although we acknowledge that each of the above mentioned arguments in support of the 
causal model has pitfalls, in aggregate our results strongly support the causal model: Menopause 
 Epigenetic age acceleration. 
In moving forward, it will be important to examine longitudinal change in epigenetic age 
of blood before and after women transition from pre- to post-menopausal status. Additionally, it 
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will be important to examine how long it takes accelerated epigenetic aging effects to become 
apparent following surgical menopause or whether they were apparent before. For instance, if 
accelerated aging is triggered by menopause, then one would expect age acceleration to increase 
as a function of time since bilateral oophorectomy. However, if the condition that led to a surgical 
removal of both ovaries (e.g. fibroids, menstrual disorders, endometriosis) is driving age 
acceleration, one would not see a linear increase in epigenetic age acceleration over time. The 
reason for bilateral oophorectomy was available from the NSHD sample. Overall, most women 
underwent bilateral oophorectomy due to reported fibroids, menstrual disorders, endometriosis (or 
some combination of these) in both groups (Table S3). Similar prevalence estimates apply to the 
blood data from PEG. 
While our study detected an association between epigenetic age in blood and age at 
menopause, similar associations were not found for epigenetic age estimates from buccal 
epithelium. One potential explanation is that aging measures in the various tissues are capturing 
different phenomena. While we find a robust correlation between AgeAccel in blood and saliva 
(r=0.70) (Figure S2), when comparing the measures of AgeAccel in women with data from both 
blood and buccal epithelium, we find that the correlation is relatively weak (r=0.20) (Figure S3). 
At first sight, the low correlation of age acceleration between tissues is surprising. However, we 
interpret it as follows. The epigenetic clock is a strong predictor of age in multiple tissue when 
comparing across individuals. However, that does not mean that it will be correlated across tissues 
when comparing within-person differences. Stress factors and other perturbations act largely in a 
tissue specific manner (37). For that reason, one may not expect all tissue within an individual to 
age at the same rate, thus potentially accounting for the low/moderate correlation between 
epigenetic age acceleration in blood and buccal epithelium.  
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To the best of our knowledge, our study is the first to demonstrate that reproductive age, 
bilateral oophorectomy, and MHT relate to measures of epigenetic age acceleration—but the 
reported associations are specific to either blood, buccal epithelium, or saliva. Future studies are 
warranted for examining these effects in other tissues. Since epigenetic age captures aspects of 
biological age (27-30), our study strongly suggests that the hormonal changes that accompany 
menopause accelerate biological aging in women. 
METHODS 
Data set 1: WHI Sample Description (blood) 
Participants were part of a subsample from the Women's Health Initiative (WHI), who were 
enrolled in an integrative genomics study with a primary aim of identifying novel genomic 
determinants of CHD. This sample included women ages 50-79, with an overrepresentation of 
racial/ethnic minorities. The WHI is a national study that began in 1993 which enrolled 
postmenopausal women. Women who were ineligible to participate in the trials or who chose not 
to be randomized were invited to participate in the observational arm of the study. The integrative 
genomics subsample employed a case-control sampling design. All cases and controls were 
required to have already undergone genome wide genotyping at baseline as well as profiling of 
seven cardiovascular biomarkers, as dictated by the aims of other ancillary WHI studies. 
 As shown in Table S1, the mean age at baseline for the 1,864 women in the WHI sample 
was 65.31 years (s.d.=7.1). AgeAccel ranged from -22.6 to 42.9, with a mean of 0.08 and a standard 
deviation of 5.3, while age at menopause ranged from age 25 to age 60, with a mean of 47.43 
(s.d.=6.9). Overall, approximately half of our sample was non-Hispanic white (47.1%), one-third 
(32.2%) were African American, and about 20% were Hispanic. The majority of our sample 
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reported never smoking (53.4%), whereas 36.4% reported past smoking history, and about 10% 
reported they were current smokers at the time of blood draw. 
 At baseline, the majority of women did not have a history of any MHT use (61.1%), while 
approximately 21% were past users and 18% were current users. Of those who had a history of 
MHT, 17% were past users of unopposed estrogen, 12% were current users of unopposed estrogen, 
6% were past users of estrogen plus progestin, and 5.5% were current users of estrogen plus 
progestin. Additionally, the majority of users were on MHT for less than five years (55%), while 
16.7% took MHT for 5-9 years, about 10% took MHT for 10-14 years, and 18% took MHT for 15 
or more years.  
Data set 2: InCHIANTI Sample Description (blood) 
The Invecchiare nel Chianti (InCHIANTI) Study is a population-based prospective cohort 
study of residents ages 30 or older from two areas in the Chianti region of Tuscany, Italy. Sampling 
and data collection procedures have been described elsewhere (38). Briefly, participants were 
enrolled between 1998-2000 and were examined at three-year intervals. Overall 1,326 participants 
donated a blood sample at baseline (1998-2000), of which 784 also donated a blood sample at the 
9-year follow-up (2007-2009). DNA methylation was assayed using the Illumina Infinium 
HumanMethylation450 platform for participants with sufficient DNA at both baseline and Year 9 
visits (n=499). Our study focused only on women (n=200). Ages for the 200 women in 
InCHIANTI ranged from 50 to 91, with a mean age of 70.64 years (Table S1), whereas baseline 
AgeAccel ranged from -12.9 to 12.05, with a mean of 0. Age at menopause ranged from age 26 to 
age 60, with a mean of 49.1. Overall, approximately 75.5% of the women from InCHIANTI were 
never smokers, 12.0% were former smoker, and about 12.5% were current smokers. Women with 
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no history of any MHT use made up 88.5% of the InCHIANTI sample. Finally, women from 
InCHIANTI averaged approximately 1.82 pregnancies over their lifetimes.  
Data set 3: Women from the PEG cohort (blood and saliva) 
We used two types of tissues from the Parkinson's disease, Environment, and Genes (PEG) 
study cohort: blood and saliva. The PEG study is a large population-based case-control study of 
Parkinson's disease of rural and township residents of California's central valley(39). Our blood 
data come from subjects from wave 1 (PEG1). Parkinson's disease status did not confound the 
relationship in blood because it was not associated with age at menopause, however we adjusted 
for it in multivariate analyses. The 256 women in PEG ranged in age from 35 to 91 years, with a 
mean age of 67.9 years (Table S1). Only 3 participants self-identified as non-Hispanic black, while 
23 self-identified as Hispanic. Average age at menopause was 46.4 years. Overall, approximately 
4% of the women from PEG were current smokers at the time of blood draw, and 38% were former 
smoker. Women with any history (current or former) of any MHT use made up 71% of the sample, 
and on average women in PEG reported having 3.4 pregnancies over their lifetimes. 
The saliva methylation data were collected at a later time point than the blood data. For 
about half of the women, we had both blood and saliva methylation data but epigenetic age 
acceleration of blood tissue was not correlated with age acceleration in saliva. 
Data set 4. NSHD (buccal epithelium) 
These buccal samples stem from a subsample of 790 women participants in a British birth 
cohort, the United Kingdom Medical Research Council National Survey of Health and 
Development (NSHD) as described in (40). The women were all aged 53 years at the time of 
sample collection in 1999. At that time, 419 women were post-menopausal and 371 women were 
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pre-menopausal. MHT status was coded as "yes" only if MHT started before the age of sample 
collection (i.e. 53). Our results regarding the relationship between "age at menopause" and 
epigenetic age acceleration were largely unchanged after excluding women who experienced 
surgical menopause. 
All women gave written informed consent for their samples to be used in genetic studies 
of health, and the Central Manchester Research Ethics Committee approved the use of these 
samples for epigenetic studies of health in 2012. Women were selected from those who provided 
a buccal and blood sample at age 53 years in 1999, who had not previously developed any cancer, 
and who had complete information on epidemiological variables of interest. Smoking status did 
not confound the reported relationships because smoking was not significantly associated with our 
measure of epigenetic age acceleration.  
DNA methylation data 
All DNA methylation data sets used the Illumina Infinium 450K platform. The Illumina 
BeadChips measures bisulfite-conversion-based, single-CpG resolution DNA methylation levels 
at 485577 different CpG sites in the human genome. These data were generated by following the 
standard protocol of Illumina methylation assays, which quantifies methylation levels by the β 
value using the ratio of intensities between methylated and un-methylated alleles. Specifically, the 
β value is calculated from the intensity of the methylated (M corresponding to signal A) and un-
methylated (U corresponding to signal B) alleles, as the ratio of fluorescent signals β = 
Max(M,0)/[Max(M,0)+Max(U,0)+100]. Thus, β values range from 0 (completely un-methylated) 
to 1 (completely methylated). For our blood data sets (WHI, PEG) we used background corrected 
beta values. Consistent with the original publication, buccal samples were normalized using the 
BMIQ method (41). The correlation between DNAm age and chronological age is highly robust 
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with respect to different normalization methods because a) the epigenetic clock implements a 
custom normalization methods and b) it was constructed using training data that were normalized 
in different ways. 
Epigenetic age acceleration 
We used the DNAm age based biomarker of aging from (15) because a) its accurate measurement 
of age across tissues is unprecedented (and it applies to both blood and buccal epithelium), b) it is 
prognostic for all-cause mortality (27, 28), c) it correlates with measures of cognitive and physical 
fitness in the elderly (27, 42), and d) it has been found useful for studying aging effects in Down 
syndrome(43), Parkinson's disease (44), neuropathological variables (42); obesity(37), and HIV 
infection(45). DNAm age was defined using the 353 CpGs and coefficient values reported in (15). 
These CpGs and coefficient values were chosen in independent data using the elastic net penalized 
regression model to regress age on CpGs, resulting in a DNAm age measures defined as predicted 
age, in years. 
Our measure of age acceleration (AgeAccel), which applies to all sources of DNA, was defined as 
residual resulting from a linear model that regressed DNAm age on chronological age.. Thus, a 
positive value for AgeAccel indicates that the observed DNAm age is higher than expected. 
AgeAccel has only a weak correlation with blood cell counts(45).  
Genome-wide SNP data from the WHI 
Genotyping was performed for all participants on Affymetrix 6.0, Illumina HumanOmni1-
Quad v1.0, or Illumina HumanOmniExpressExome-8v1.0. Imputation was performed using 
MaCH with haplotypes phased in Beagle or Minimac(46, 47). The reference panel for imputation 
was based on the 1000 Genome haplotypes (released in June 2011). The quality of imputed 
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markers was assessed by MaCH R2 > 0.3. Additional quality control filters that were employed 
included Hardy-Weinberg Equilibrium P-values <10-3 and minor allele frequency (MAF) >0.01. 
Finally, to account for population structure, principal component analysis (PCA) was performed 
to generate sample eigenvectors, the first two of which were included as covariates in all GCTA 
analysis.  
We related the two highly significant SNPs from the recent large-scale meta-analysis of 
age at menopause(31) to age acceleration using the WHI data. Association analysis was conducted 
in the two subsets of individuals stratified by platform. All women were of European ancestry, 
identified by multidimensional scaling analysis in PLINK. We combined the results into a single 
estimate by fixed-effects models weighted by inverse variance, as implemented in R metafor. For 
association analysis, we regressed each of the three age acceleration trait values on expected 
genotype dosage, adjusted for the first two principal components when necessary.  
Ethics 
This study was reviewed by institutional review board from UCLA (IRB#13-000671 and 
IRB#14-000061). Informed consent was obtained from all subjects. 
Availability of data 
The WHI and inCHIANTI data are available through NHLBI 
(https://biolincc.nhlbi.nih.gov/studies/bhs/). The PEG data are available from Gene Expression 
Omnibus (GSE72775).  
Software Code Availability 
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We used the online version of the epigenetic clock software, which is freely available from 
the following webpage: https://dnamage.genetics.ucla.edu/. R source code is publicly available 
(from Additional file 20 in Horvath (2013) Genome Biology, PMID: 24138928). 
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FIGURE LEGENDS 
 
Figure 1: Epigenetic age acceleration versus surgical menopause status. The x-axis of each 
plot reports surgical menopause status before age 50, i.e. "yes" denotes the group of women with 
surgical menopause before age 50 whereas "no" corresponds to the group of women who did not 
undergo bilateral oophorectomy at any age before blood draw. The bar plots report mean values 
of AgeAccel, one standard error, and the p-value from a Student T test. The six panels correspond 
to (A) WHI (white), (B) WHI (black), (C) WHI (Hispanic), (D) InCHIANTI, and (E) PEG samples, 
and (F) all samples combined. A meta-analysis based on Stouffer's Z method indicates that 
AgeAccel is significantly positively associated with surgical menopause status (p=0.0018).  
Figure 2: Epigenetic age analysis of buccal samples from NSHD. The measure of age 
acceleration was defined as the difference between DNAm age and the mean DNAm age in this 
birth cohort. The scatter plots also report Pearson correlation coefficients and corresponding p-
values, while the bar plot report one standard error and the p-value from a non-parametric group 
comparison test (Kruskal Wallis). Epigenetic age acceleration (y-axis) is associated with (A) MHT 
(P=0.00078), but not with (B) age at menopause, (C) menopausal status, or (D) surgical 
menopause.  
Figure 3: Epigenetic age analysis of saliva samples from PEG. The measure of age acceleration 
in saliva was defined in the same way as blood. The scatter plots report Pearson correlation 
coefficients and corresponding p-values, while the bar plot report one standard error and the p-
value from a non-parametric group comparison test (Kruskal Wallis). There is a strong correlation 
between epigenetic age (y-axis) and chronological age (A). While the correlation between 
epigenetic age acceleration and age at menopause in saliva (B) is about twice that of the association 
in blood, the finding is not significant. However, we do observe an association between epigenetic 
age acceleration and (C) surgical menopause (P=0.0079).  
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TABLES  
 
 
Table 1. Unadjusted Meta-analysis of AgeAccel in Blood versus Age at Menopause  
 Meta-Analysis Z statistics (P-values) 
Measure Removed age at 
menopause<=30 
Removed surgical 
menopause 
All 
AgeAccel 3.3 (p=0.00091) 2.6 (p=0.0083) 2.7 (p=0.0061) 
Meta-analysis based on Pearson correlations between age at menopause and AgeAccel in each 
sample. The first and second column correspond to analysis after excluding women who were 30 
or younger at the age of menopause and women with surgical menopause, respectively. The last 
column reports findings with no exclusions applied. 
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Table 2: Multivariate Meta-analysis of AgeAccel in Blood versus Age at Menopause 
  Beta Coefficient (P-value)  
  WHI InCHIANTI PEG Meta P-Value 
AgeAccel     
 Age at Menopause -0.063 (0.001) -0.012 (0.772) -0.060 (0.350) 8.32×10
-4 
 Chronological Age 0.012 (0.530) -0.010 (0.825) -0.051 (0.305)  
 Non-Hispanic 
Black 
0.008 (0.980) 
-- 
-5.113 (0.201)  
 Hispanic -0.918 (0.008) -- -1.905 (0. 321)  
 Former Smoker -0.312 (0.234) 0.446 (0.648) -1.177 (0.238)  
 Current Smoker -0.189 (0.666) -0.870 (0.394) -1.378 (0.613)  
 MHT 0.041 (0.871) 0.940 (0.368) 2.864 (0.018)  
 Age at Menarche -0.055 (0.501) 0.280 (0.179) -0.020 (0.950)  
 PD Status -- -- 1.075 (0.282)  
We did not adjust for race/ethnicity in the models run for InCHIANTI, given that all participants are non-Hispanic 
white. For all models, women with age at menopause <30 years were excluded. 
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Table 3: GCTA Bivariate REML Results  
  
h2 of AgeAccel (SE) 0.651 (0.13) 
h2 of Age at Menopause (SE) 0.384 (0.14) 
rG (Pvalue) -0.256 (0.054) 
V(G) (SE) 18.71 (3.90) 
C(G) (SE) -4.70 (3.69) 
V(e) (SE) 10.03 (3.61) 
C(e) (SE) 1.69 (3.47) 
Vp (SE) 28.74 (0.93) 
Log likelihood -9017.31 
rG=Genetic correlation with age at menopause, V(G)=Genetic Variance; C(G)=Genetic 
Covariance with age at menopause; V(e)=Residual Variance; C(e)=Residual Covariance 
with age at menopause; h2= Heritability (Proportion of Variance explained by all SNPs) 
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Table 4: Mendelian Randomization 
CHR 
 
SNP 
 
bp 
 
Minor/Major  
Alleles 
with respect to minor allele P-value) 
AgeAccel  
19 rs11668344 55833664 G/A 0.506 (0.031) 
20 rs16991615 5948227 A/G 0.151 (0.763) 
 
 
